Literature DB >> 8699228

Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

M A Hammoud1, R Sawaya, W Shi, P F Thall, N E Leeds.   

Abstract

Tumor necrosis, enhancement, and associated edema in patients with glioblastoma multiforme (GBM) represent biological variables that can be quantitated on preoperative MRI scans. We reviewed 48 highly selected patients, all of whom had supratentorial lesions, had undergone gross total tumor resection, and had received adjuvant treatments (radio- and chemotherapies). None of these patients had had surgery for recurrent tumor resection and none had harbored multifocal tumors. The median age was 50 years. The median Karnofsky performance score was 80. Multivariate analysis using the Cox regression model revealed that the strongest prognostic variable was the amount of tumor necrosis on preoperative scan (P < 0.001), with median survivals of 42, 24, 15, and 12 months for tumor necrosis grades of 0 (7 'pts'), I (11 'pts'), II (9 'pts'), and III (21 'pts'), respectively. The intensity of enhancement of the tumor nodule was another prognostic factor (P = 0.003), with median survivals of 35, 18, and 13.5 months for enhancement grades of 0 (2 'pts'), I (22 'pts'), and II (24 'pts'), respectively. The extent of peritumoral edema had a quadratic effect (P = 0.001), with grades I (19 'pts'), II (22 'pts'), and III (7 'pts') surviving for 24, 12, and 20 months respectively. Location and volume of tumors were not statistically significant predictors of survival (P < 0.05). In conclusion, in this highly selected group, GBM patients with little or no necrosis and with less tumor nodule enhancement on preoperative MRI survive longer than patients with greater amounts of necrosis and greater degrees of tumor enhancement. In addition, a moderate degree of peritumoral edema is associated with worse prognosis.

Entities:  

Mesh:

Year:  1996        PMID: 8699228     DOI: 10.1007/bf00146086

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

Review 1.  Vascular structures in brain tumors.

Authors:  A Hirano; T Matsui
Journal:  Hum Pathol       Date:  1975-09       Impact factor: 3.466

2.  Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas.

Authors:  M Ammirati; N Vick; Y L Liao; I Ciric; M Mikhael
Journal:  Neurosurgery       Date:  1987-08       Impact factor: 4.654

3.  Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use.

Authors:  D A KARNOFSKY; J H BURCHENAL; G C ARMISTEAD; C M SOUTHAM; J L BERNSTEIN; L F CRAVER; C P RHOADS
Journal:  AMA Arch Intern Med       Date:  1951-04

Review 4.  Blood-brain barrier: phenomenon of increasing importance to the imaging clinician.

Authors:  M R Sage
Journal:  AJR Am J Roentgenol       Date:  1982-05       Impact factor: 3.959

5.  Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas.

Authors:  M C Chamberlain; J A Murovic; V A Levin
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

6.  Survival in glioblastoma: historical perspective.

Authors:  M Salcman
Journal:  Neurosurgery       Date:  1980-11       Impact factor: 4.654

7.  Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas.

Authors:  V A Levin; W F Hoffman; D C Heilbron; D Norman
Journal:  J Neurosurg       Date:  1980-05       Impact factor: 5.115

8.  Epilepsy and other factors in the prognosis of gliomas.

Authors:  G M Scott; F B Gibberd
Journal:  Acta Neurol Scand       Date:  1980-04       Impact factor: 3.209

Review 9.  Is necrosis helpful in the grading of gliomas? Editorial opinion.

Authors:  E C Alvord
Journal:  J Neuropathol Exp Neurol       Date:  1992-03       Impact factor: 3.685

10.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

View more
  113 in total

1.  Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.

Authors:  Christian Henker; Thomas Kriesen; Katharina Fürst; Deborah Goody; Änne Glass; Brigitte M Pützer; Jürgen Piek
Journal:  J Neurooncol       Date:  2015-11-25       Impact factor: 4.130

2.  A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.

Authors:  Makoto Ideguchi; Takafumi Nishizaki; Norio Ikeda; Tomomi Okamura; Yasue Tanaka; Natsumi Fujii; Machiko Ohno; Taichi Shimabukuro; Tokuhiro Kimura; Eiji Ikeda; Kazuyoshi Suga
Journal:  J Neurooncol       Date:  2018-03-07       Impact factor: 4.130

Review 3.  A review of the automated detection of change in serial imaging studies of the brain.

Authors:  Julia Patriarche; Bradley Erickson
Journal:  J Digit Imaging       Date:  2004-06-29       Impact factor: 4.056

4.  Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.

Authors:  Rihyeon Kim; Seung Hong Choi; Tae Jin Yun; Soon-Tae Lee; Chul-Kee Park; Tae Min Kim; Ji-Hoon Kim; Sun-Won Park; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Eur Radiol       Date:  2016-06-29       Impact factor: 5.315

5.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

6.  Inhibition of cystine uptake disrupts the growth of primary brain tumors.

Authors:  Wook Joon Chung; Susan A Lyons; Gina M Nelson; Hashir Hamza; Candece L Gladson; G Yancey Gillespie; Harald Sontheimer
Journal:  J Neurosci       Date:  2005-08-03       Impact factor: 6.167

7.  Early stage glioblastoma: retrospective multicentric analysis of clinical and radiological features.

Authors:  Isabella Ceravolo; Giovanni Barchetti; Francesco Biraschi; Carmela Gerace; Enrico Pampana; Alberto Pingi; Alessandro Stasolla
Journal:  Radiol Med       Date:  2021-08-02       Impact factor: 3.469

8.  CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities.

Authors:  Charles B Stevenson; Moneeb Ehtesham; Kathryn M McMillan; J Gerardo Valadez; Michael L Edgeworth; Ronald R Price; Ty W Abel; Khubaib Y Mapara; Reid C Thompson
Journal:  Neurosurgery       Date:  2008-09       Impact factor: 4.654

9.  Non-enhancing de novo glioblastoma: report of two cases.

Authors:  Aaron A Cohen-Gadol; Michael L DiLuna; Sergei I Bannykh; Joseph M Piepmeier; Dennis D Spencer
Journal:  Neurosurg Rev       Date:  2004-07-28       Impact factor: 3.042

10.  Coincidence of central neurocytoma and multiple glioblastomas: a rare case report.

Authors:  Yoshihiro Muragaki; Mikhail Chernov; Yasuhiko Tajika; Osami Kubo; Hiroshi Iseki; Tomokatsu Hori; Kintomo Takakura
Journal:  J Neurooncol       Date:  2009-01-29       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.